OneSource Specialty gets EIR with VAI status for BLD facility in Bangalore

29 Jan 2025 Evaluate

OneSource Specialty Pharma has received an Establishment Information Report (EIR) with a 'Voluntary Action Indicated' (VAI) status from the U.S. Food and Drug Administration (USFDA) for its BLD facility in Bangalore. The report follows an inspection of the facility, conducted from November 14 - 22, 2024.

OneSource operates five state-of-the-art cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies.  

OneSource Specialty Pharma formerly known as Stelis Biopharma, is India’s first specialty pharma pure-play CDMO business.

Onesource Specialty Share Price

1537.70 -105.00 (-6.39%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1371.55
Zydus Lifesciences 884.85
Lupin 2165.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×